Tonix Pharmaceuticals (US:TNXP) Newsfilter·2024-06-11 21:17Core Viewpoint - Tonix Pharmaceuticals Holding Corp. plans to offer and sell shares of its common stock or pre-funded warrants, with the offering subject to market conditions and no assurance on completion or terms [2][3]. Group 1: Offering Details - The company intends to use the net proceeds from the offering for working capital, general corporate purposes, and preparation of a new drug application for its Tonmya™ product candidate targeting fibromyalgia [3]. - Dawson James Securities, Inc. is the sole placement agent for the offering [4]. - The offering is being made under an effective shelf registration statement previously filed with the SEC [9]. Group 2: Company Overview - Tonix is a fully-integrated biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) disorders and other diseases [5]. - The company aims to submit a New Drug Application (NDA) for Tonmya™ in the second half of 2024, following two successful Phase 3 studies for fibromyalgia management [5]. - Tonix's product portfolio includes TNX-102 SL for fibromyalgia and acute stress reaction, TNX-1300 for cocaine intoxication, and TNX-1500 for organ transplant rejection and autoimmune diseases [5][6].